Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Melatonin reprograms antioxidant defenses to suppress ferroptosis via Homer1a/mGluR1-Nrf2/xCT signaling after retinal ischemia-reperfusion.

Redox biology·2026

Same author

Coherent twins for manufacturing thick lithium-rich battery positive electrodes.

Nature nanotechnology·2026

Same author

Targeting AMPK signaling in nucleus pulposus cells ameliorates spaceflight microgravity-induced intervertebral disc degeneration.

Cell death and differentiation·2026

Same author

Skeletal muscle‑derived extracellular vesicles in multi‑organ degenerative disease: Mechanisms and therapeutic delivery perspectives (Review).

International journal of molecular medicine·2026

Same author

Disruption of YAP biomolecular condensates by mechanical stress drives intervertebral disc vascularization.

Science advances·2026

Same author

Optimization of Thulium Fiber Laser Lithotripsy Efficacy Based on Multidimensional Parameter Combination Strategies.

European urology open science·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2025

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

Lactobacillus-Polydopamine System for Targeted Drug Delivery in Overactive Bladder: Evidence from Bladder Cell

Xiaolong Wang^1,2, Guanyi Wang², Peibin Cen¹

¹Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.

International Journal of Nanomedicine

|August 20, 2024

Summary

A novel Lactobacillus-polydopamine nanoparticle system effectively delivers medication directly to the bladder wall, improving overactive bladder (OAB) treatment. This targeted bacteriotherapy offers a promising alternative to systemic OAB drugs.

Keywords:

drug delivery lactobacillus nano material overactive bladder polydopamine

More Related Videos

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Related Experiment Videos

Last Updated: Jun 16, 2025

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Area of Science:

Biomedical Engineering
Nanotechnology
Microbiology

Background:

Overactive bladder (OAB) presents significant challenges due to limited treatment efficacy, side effects, and poor patient compliance.
Novel drug delivery systems targeting the bladder wall are needed to improve OAB therapy.

Purpose of the Study:

To explore a polydopamine (PDA)-coated lactobacillus platform as a novel carrier for localized OAB treatment.
To evaluate the efficacy of this Lactobacillus-PDA system (LPS) in delivering the antimuscarinic drug solifenacin in an OAB rat model.

Main Methods:

Urinary microbiome profiling to identify lactobacillus prevalence in healthy and OAB groups.
Synthesis and characterization of Lactobacillus-PDA nanoparticles.
Assessment of nanoparticle distribution and penetration using rat bladder perfusion models and human bladder smooth muscle cell spheroids.
Evaluation of LPS efficacy in an OAB rat model.

Main Results:

Lactobacillus was identified as a dominant genus in the urinary microbiome of both healthy and OAB individuals.
Synthesized Lactobacillus-PDA nanoparticles demonstrated uniform size and optical properties.
Nanoparticles showed successful distribution and penetration into bladder tissues without observed toxicity.
The LPS effectively delivered solifenacin, leading to improved treatment outcomes in the OAB rat model.

Conclusions:

The Lactobacillus-PDA system (LPS) shows significant promise as a targeted drug carrier for OAB therapy.
This bacteriotherapy approach, utilizing probiotic bacteria and nanoparticles, may overcome limitations associated with current systemic OAB medications.
The ability of PDA-coated lactobacillus to penetrate bladder tissues supports its potential for localized drug delivery in OAB treatment.